Depomed (DEPO) Misses Q4 EPS by 13c

Depomed (NASDAQ: DEPO) reported Q4 EPS of $0.16, $0.13 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $111.2 million versus the consensus estimate of $110.24 million.

Non-GAAP adjusted earnings includes a reduction of $10 million, or $0.13 cents per share related to the tax treatment of the cebranopadol transaction.

For earnings history and earnings-related data on Depomed (DEPO) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• Premarket movers: Oracle surges on AI growth, ACV auctions jumps on $1.9B deal